Health Blueprint

Back to Longevity News

News summary

Traded: Venture Capital 🦄 on Instagram: "Precision Neuroscience closed an oversubscribed $250 million Series D co-led by Pershing Square Inc., the Ackman Oxman Institute and an undisclosed leading life sciences investment fund, bringing its total funding to $430 million. The brain-computer interface company, led by co-founder and CEO Michael Mager, plans to use the capital to expand clinical programs, advance FDA review of its Layer 7 cortical interface and build commercialization infrastructure. FOUNDERS: Michael Mager & Dr. Benjamin Rapoport INVESTORS: Pershing Square Inc., Ackman Oxman Institute, Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures & JSL Health Capital ROUND: Series D AMOUNT: $250,000,000 HQ: New York City, New York #VentureCapital #PrecisionNeuroscience #MichaelMager #TradedVC"

Source: traderVC • Published: 24 Sept 2026, 21:19

Summarized by Masters of Longevity from traderVC.

Precision Neuroscience — a brain–computer interface company — is featured in an article about its latest major fundraising and growth plans, offering readers insight into an investor-backed scale-up moving toward clinical and commercial milestones.

Traded: Venture Capital 🦄 on Instagram: "Precision Neuroscience closed an oversubscribed $250 million Series D co-led by Pershing Square Inc., the Ackman Oxman Institute and an undisclosed leading life sciences investment fund, bringing its total funding to $430 million. The brain-computer interface company, led by co-founder and CEO Michael Mager, plans to use the capital to expand clinical programs, advance FDA review of its Layer 7 cortical interface and build commercialization infrastructure. FOUNDERS: Michael Mager & Dr. Benjamin Rapoport INVESTORS: Pershing Square Inc., Ackman Oxman Institute, Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures & JSL Health Capital ROUND: Series D AMOUNT: $250,000,000 HQ: New York City, New York #VentureCapital #PrecisionNeuroscience #MichaelMager #TradedVC"
Key Takeaways
  • Precision Neuroscience raised an oversubscribed $250 million Series D to accelerate its development and operations.
  • The company will use the funds to expand clinical programs and advance FDA review of its Layer 7 cortical interface.
  • Proceeds will also support building commercialization infrastructure to prepare the product for market adoption.
Read the full article at traderVC ↗

Continue exploring

Recommended MoL Picks

MoL PickFrom Metrics to Better LivingEverstride’s May 2026 Consumer Health Market Briefing shows a wellness market moving from products to systems, from tracking to guidance, and from optimization to meaning. The next winners in longevity may not be the companies that measure the most. They may be the ones that help consumers translate health data into a life they actually want to live.MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.